Table II.
Open in new tab
Characteristics of the peptides used in this study
VirusPeptide nameProteinSequenceHLA-A*0101 positiveHLA-A*2601 positiveReferences
SARS-CoV-2STSORF1ab 483–491STSAFVETV++(54)
YTTORF1ab 1873–1882YTTTIKPVTY++(48, 49)
EIDORF1ab 1891–1899EIDPKLDNY++(48)
CTE-11ORF1ab 1889–1899CTEIDPKLDNY+(49)
EVGORF1ab 2089–2099EVGHTDLMAAY+(48)
NST-10ORF1ab 2272–2281NSTNVTIATY+(48)
STNORF1ab 2273–2281STNVTIATY+(48)
SEFORF1ab 3946–3954SEFSSLPSY++(54)
VATM 170–178VATSRTLSY++(54)
YTN-10S 28–37YTNSFTRGVY++(48)
YTN-11S 28–38YTNSFTRGVYY+(49)
NSFS 30–38NSFTRGVYY+(48)
WTAS 258–266WTAGAAAYY++(48, 55)
EVFS 340–351EVFNATRFASVY+(48)
NSTS 343–351NSTRFASVY+(56)
CVAS 361–369CVADYSVLY++(48, 55)
TSNS 604–612TSNQVAVLY++(48, 56)
IAVHSNNP 140–148HSNLNDATY++(57)
YSHPB1 30–38YSHGTGTGY++(57)
LVSPB1 590–599LVSDGGPNLY++(57)
CTENP 44–52CTELKLSDY+(56)
HPV-16DVML1 412–420DVMTYIHSM+Screening from our laboratory
YVAL1 53–61YVARTNIYY+
VirusPeptide nameProteinSequenceHLA-A*0101 positiveHLA-A*2601 positiveReferences
SARS-CoV-2STSORF1ab 483–491STSAFVETV++(54)
YTTORF1ab 1873–1882YTTTIKPVTY++(48, 49)
EIDORF1ab 1891–1899EIDPKLDNY++(48)
CTE-11ORF1ab 1889–1899CTEIDPKLDNY+(49)
EVGORF1ab 2089–2099EVGHTDLMAAY+(48)
NST-10ORF1ab 2272–2281NSTNVTIATY+(48)
STNORF1ab 2273–2281STNVTIATY+(48)
SEFORF1ab 3946–3954SEFSSLPSY++(54)
VATM 170–178VATSRTLSY++(54)
YTN-10S 28–37YTNSFTRGVY++(48)
YTN-11S 28–38YTNSFTRGVYY+(49)
NSFS 30–38NSFTRGVYY+(48)
WTAS 258–266WTAGAAAYY++(48, 55)
EVFS 340–351EVFNATRFASVY+(48)
NSTS 343–351NSTRFASVY+(56)
CVAS 361–369CVADYSVLY++(48, 55)
TSNS 604–612TSNQVAVLY++(48, 56)
IAVHSNNP 140–148HSNLNDATY++(57)
YSHPB1 30–38YSHGTGTGY++(57)
LVSPB1 590–599LVSDGGPNLY++(57)
CTENP 44–52CTELKLSDY+(56)
HPV-16DVML1 412–420DVMTYIHSM+Screening from our laboratory
YVAL1 53–61YVARTNIYY+
Table II.
Open in new tab
Characteristics of the peptides used in this study
VirusPeptide nameProteinSequenceHLA-A*0101 positiveHLA-A*2601 positiveReferences
SARS-CoV-2STSORF1ab 483–491STSAFVETV++(54)
YTTORF1ab 1873–1882YTTTIKPVTY++(48, 49)
EIDORF1ab 1891–1899EIDPKLDNY++(48)
CTE-11ORF1ab 1889–1899CTEIDPKLDNY+(49)
EVGORF1ab 2089–2099EVGHTDLMAAY+(48)
NST-10ORF1ab 2272–2281NSTNVTIATY+(48)
STNORF1ab 2273–2281STNVTIATY+(48)
SEFORF1ab 3946–3954SEFSSLPSY++(54)
VATM 170–178VATSRTLSY++(54)
YTN-10S 28–37YTNSFTRGVY++(48)
YTN-11S 28–38YTNSFTRGVYY+(49)
NSFS 30–38NSFTRGVYY+(48)
WTAS 258–266WTAGAAAYY++(48, 55)
EVFS 340–351EVFNATRFASVY+(48)
NSTS 343–351NSTRFASVY+(56)
CVAS 361–369CVADYSVLY++(48, 55)
TSNS 604–612TSNQVAVLY++(48, 56)
IAVHSNNP 140–148HSNLNDATY++(57)
YSHPB1 30–38YSHGTGTGY++(57)
LVSPB1 590–599LVSDGGPNLY++(57)
CTENP 44–52CTELKLSDY+(56)
HPV-16DVML1 412–420DVMTYIHSM+Screening from our laboratory
YVAL1 53–61YVARTNIYY+
VirusPeptide nameProteinSequenceHLA-A*0101 positiveHLA-A*2601 positiveReferences
SARS-CoV-2STSORF1ab 483–491STSAFVETV++(54)
YTTORF1ab 1873–1882YTTTIKPVTY++(48, 49)
EIDORF1ab 1891–1899EIDPKLDNY++(48)
CTE-11ORF1ab 1889–1899CTEIDPKLDNY+(49)
EVGORF1ab 2089–2099EVGHTDLMAAY+(48)
NST-10ORF1ab 2272–2281NSTNVTIATY+(48)
STNORF1ab 2273–2281STNVTIATY+(48)
SEFORF1ab 3946–3954SEFSSLPSY++(54)
VATM 170–178VATSRTLSY++(54)
YTN-10S 28–37YTNSFTRGVY++(48)
YTN-11S 28–38YTNSFTRGVYY+(49)
NSFS 30–38NSFTRGVYY+(48)
WTAS 258–266WTAGAAAYY++(48, 55)
EVFS 340–351EVFNATRFASVY+(48)
NSTS 343–351NSTRFASVY+(56)
CVAS 361–369CVADYSVLY++(48, 55)
TSNS 604–612TSNQVAVLY++(48, 56)
IAVHSNNP 140–148HSNLNDATY++(57)
YSHPB1 30–38YSHGTGTGY++(57)
LVSPB1 590–599LVSDGGPNLY++(57)
CTENP 44–52CTELKLSDY+(56)
HPV-16DVML1 412–420DVMTYIHSM+Screening from our laboratory
YVAL1 53–61YVARTNIYY+
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close